M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he has been publishing, during the past year and a half, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech sector is unmatched during that time.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
Zvi is a legal and marketing consultant. Zvi provides advisory services to companies, trusts and individuals, including consulting expert services regarding marketing compliance, securities regulations and evaluations of potential fiduciary liability. No articles or discussions here shall constitute a legal, fiduciary or advisory role, but solely act as informative press and/or a starting point from which, ideally, further constructive discussion may follow. Comments are welcome, as are questions.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
I spent five years as an implantable neurological device sales rep and am now earning income as a commercial risk broker and small cap biotech investor/trader. I enjoy small cap stock analysis and speculative trades. My patience and understanding of market psychology help me get by. I also enjoy traveling to warmer climates and crossfit workouts.
Brian Ganch is a freelance journalist. His interests are multifaceted and span from music (Bachelor of music performance in Percussion--performs in a Pennsylvania based Symphony Orchestra), to electronics, to biotechnology.
He follows technology, music and entertainment, pharmaceutical and biotechology firms in the market place.
John Eastman is a writer, mixed media artist, and founder of several businesses (www.redfishcreative.com) (www.eastmantribe.com)with over 25 years of hands-on business and entrepreneurial experience. He currently works and resides in a studio loft in Pittsburgh, Pennsylvania and NYC. Mr. Eastman has exhibited and read in various galleries and exhibits in the region as an artist and writer.
Mr. Eastman is the co-founder of www.smallcapcity.com, an online publication that focuses on small capitalized public firms, founder of www.blackandwhiteprogram.com, an online publication offering interviews, essays, and reports. He also writes for www.thechairmansblog.com, www.smallcapcity.com, Motley Fool, and several other online and print publications.
Mr. Eastman’s business background commenced in 1985 with the launch of a series of high tech, real estate, and design firms. He has extensive experience in banking and loan servicing, real estate property management and asset management, asset appraisal and valuation, Office of Thrift Supervision (OTS) and FDIC bank closure proceedings.
Mr. Aberman joined Pluristem as Chairman & CEO in September 2005. Upon arrival he immediately changed the Company’s strategy towards cellular therapeutics. Mr. Aberman's vision to use the maternal section of the Placenta (Decidua) as a source for cell therapy, combined with Pluristem’s 3D culturing technology, led to the development of a series of unique products.
Mr. Aberman has 20 years of experience in marketing and management within the high technology industry. He has held positions as Chief Executive Officer and Chairman in Israel, the USA, Europe, Japan and Korea. He has operated within high-tech global companies in the fields of automatic optical inspection, network security, video over IP, software, chip design and robotics. Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company. He has served in the past as the Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP and as a Director of Ori Software Ltd., a company involved in data management. Prior to that, he served as the President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronic industry.
Mr. Aberman has served as President and CEO of Netect Ltd., specializing in the field of internet security software and was the Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing. He has also served as Chairman of Display Inspection Systems Inc., specializing in laser based inspection machines and as President and CEO of Robomatix Technologies Ltd. (RBMXF.OB).
In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel.
Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.
MarketScanners is a newsletter featuring Market Scans and Trading Ideas based on many different types of fundamentals scans, market analytics and technical analysis. Coupled with fundamentals and news catalysts, some of the plays we highlight for investors tend to move quickly and make great candidates for momentum traders and others seeking quick picks based on solid analysis and research.
Some companies featured in our newsletter pay MarketScanners for research, analysis, articles and distribution. Our reports contain forward-looking statements relating to the developments of the featured company’s products, services, future operating results and the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
Since we are often compensated in shares or cash for our services, investors should evaluate the information on the Site with that in mind and should always perform their own independent analysis.
Paul has been managing Noble Equity Fund, LP, a healthcare-focused hedge fund, since January of 2008. In addition, he manages Noble Advisors, LLC, a Registered Investment Advisor. Prior to this, he worked on the sell side at Sidoti & Co. and Deutsche Bank covering various industries. Mr. Nouri graduated from Rensselaer Polytechnic Institute, in 2005, with a Bachelors of Science in Finance and graduated from Yale School of Management in 2017 with a MBA.
StocksnSectors is an emerging forum focused on undiscovered micro-cap companies – in three key sectors we believe are headed for substantial growth over the next decade: (1) Healthcare, (2) Internet and IT, and (3) Energy and Environmentally Clean Technology. Micro-cap companies typically lack Wall Street analyst coverage, and are inefficiently priced and/or often thinly trading the proverbial “tree in the forest.” Click link below read disclaimer section:
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
My firm provides investment products and solutions for institutions and individual investors. I take particular attention to small and mid-cap companies in emerging markets. I like to research and trade good ideas; both long and short; with other experienced traders.
Irfan Cehajic is the managing editor of the TechnicalBuy Investment Newsletter and the TechnicalBuy Alert Service publications. Since 2007 TechnicalBuy has built a reputation for solid research, unique investment ideas, and comprehensive coverage of mining, biotech, and oil and gas small-cap companies. Irfan's research is based on building strong relationships and staying in touch with CEOs, fund managers, PhDs, MDs, geologists, and other industry experts.
Irfan has a BASc in Computer Engineering, working in software-startups in Toronto, Canada.
I am a personal investor and an attorney. I have extensive experience in the consumer credit arena as well as commercial real estate as an investor and a lender. I co-manage a commercial, hard money mortgage fund and also have experience with the Food, Drug & Cosmetic Act.
Bert J. Wilkison, of Chicago, IL, is the CEO and a Managing Member at Kinetic Investments, a subsidiary of Wilkison Financial, LLC. He is also an active pooled funds manager who enjoys stock picking, trading, ETF strategizing and finding long-term value plays ahead of the ever-evolving markets. Lastly, he handles intricate and involved corporate negotiations, as a third party, on a commission basis.
Follow him on twitter @KineticInvestor or e-mail him for additional commentary at email@example.com.
Areas of focus: Gold, Mining, Oil/Nat Gas, Rare Earth Elements and Metals, Healthcare/Biotech, Energy, Tech, ETFs, Consumer Goods, Utilities, and Services.
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
Full Time Micro Cap Investor. Founder of MicroCapClub.com
Founded in 2011, MicroCapClub is an exclusive forum for experienced microcap investors focused on microcap companies (sub $300m market cap). MicroCapClub was created to be a platform for experienced microcap investors to share and discuss stock ideas. MicroCapClub’s mission is to foster the highest quality microcap investor Community, produce Educational content for investors, and promote better Leadership in the microcap arena.
The enormous advancement in the biological sciences that is taking place has begun to change the traditional way of practicing medicine. Far-reaching biological products are being approved and news about breakthroughs are occupying the media headlines. However, selecting the biotechnology firms for investment requires not only an understanding of the company's finances, but also deep knowledge of the company's potential and the potential and scientific validity of it's products and technologies.
Our Mission is evaluating biotechnology companies, their products, their technologies, scientists, managements, as well as their finances. Our goal is to impart our readers with the knowledge and insight so that they may have a heightened understanding and appreciation for the biotechnology industry.
The Prohost Letter has been in circulation since 1992. Our readers are comprised of venture capital, fund managers, investors, medical professionals and individuals with one common interest, biotechnology.
Prohost Letter is posted in the members areas on the www.prohostbiotech.com. around 40 times a year. Articles are posted several times a week for subscribers in TODAY'S HIGHLIGHTS section and in News & Comments sector for all website visitors
Dr. John L. Faessel is a seasoned and respected Wall Street professional with industry-wide recognition for expertise in market strategy and analysis. He is widely recognized for his insights in public companies. For over 20-years Dr. Faessel’s ON THE MARKET reports have been widely distributed to a throughout the world to an extensive list of financial institutions, investment banking firms, brokers, foundations, mutual funds, hedge funds and private high net worth investors. Dr. Faessel is also a daily contributor to the widely read JagNotes.com, Wall Streets oldest daily rag.
Brandon Matthews (pseudonym) is the founder of SatwavesPro.com, which was borne of his desire to help retail investors after witnessing the continually changing ways that Wall Street can cheat them. Brandon has worked for Monroe Parker Investment Bankers, Morgan Stanley Dean Witter, American Express Financial Advisors, David Lerner Associates and a private equity firm as a stock and bond broker.
Brandon held Series 7, 63, 65, 31, Life, Health, Variable Annuity and Variable Life Securities and Insurance Licenses and was a registered investment advisor in New York, New Jersey, Florida and Connecticut.
Brandon combines an expertise in point & figure technical analysis with basic fundamental research to provide actionable recommendations.
Brandon is a Gold Level Contributor to Seeking Alpha and a top ranked author, had a significant role as an expert in the documentary Stock Shock, and is working on his first book.
Marc is a frequent contributor to Investment U and also The Oxford Club’s Income Specialist and Editor of The Oxford Income Letter. He is the author of the best seller "Get Rich with Dividends".
His investment career started out at the trading desk of Carlin Equities in San Francisco, CA, where he executed dozens of trades each day for his clients.
As a Senior Analyst with Avalon Research Group, his buy recommendation gained 17.8% versus the S&P 500′s 5.9%. While there, Marc started and headed the technical research products division, in addition to his fundamental duties.
Marc also looked at the market with a journalist’s skeptical eye as a columnist for The Street, where he broke several stories on companies in the biotech sector. His contrarian recommendations (including shorts) gained 12.6% annualized versus the S&P 500′s gain of 0.5%.
Along with Oxford Club publications, Marc has appeared on Fox Business, Bloomberg Radio, Yahoo! Finance and been published in the online version of The Wall Street Journal, The Street, U.S News and World Report and was featured on NPR’s “The Story.”
Disclaimer: Money Morning and Stansberry & Associates Investment Research are separate companies, and entirely distinct. Their only common thread is a shared parent company, Agora Inc. Agora Inc. was named in the suit by the SEC and was exonerated by the court, and thus dropped from the case. Stansberry & Associates was found civilly liable for a matter that dealt with one writer’s report on a company. The action was not a criminal matter. The case is still on appeal, and no final decision has been made.
Kapitall is the online finance platform for the next generation, where investing is as easy as drag, drop and trade. With an intuitive and playful user experience, Kapitall offers tools that make it easy to build virtual and real brokerage portfolios, share ideas and research stocks and funds.